Staphylococcus aureus vaccine conjugate pentavalent - GlaxoSmithKline

Drug Profile

Staphylococcus aureus vaccine conjugate pentavalent - GlaxoSmithKline

Alternative Names: PentaStaph; StaphVAX-Pentavalent

Latest Information Update: 16 Sep 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Nabi Biopharmaceuticals
  • Developer Biota Pharmaceuticals; GlaxoSmithKline
  • Class Bacterial vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Gram-positive infections; Staphylococcal infections

Most Recent Events

  • 10 Aug 2010 Milestone payment triggered to be made by GlaxoSmithKline Biologicals to Nabi Biopharmaceuticals
  • 09 Dec 2009 Phase-I/II clinical trials in Gram-positive infections (Prevention) in USA (IM)
  • 09 Dec 2009 Phase-I/II clinical trials in Staphylococcal infections (Prevention) in USA (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top